Note Regarding Forward Looking Statements

Statements on this website regarding our strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements regarding the potential benefits of our product(s) and product candidate(s); the rate and timing of enrollment of our clinical trials; the timing of top-line results of our clinical trials; the potential benefits of the combined company post-merger; the market and growth potential of our product(s); and collaborations and partnerships. Actual results could differ materially from the expectations and projections set forth in those statements. The terms “anticipate,” “believe,” “expect,” “opportunity,” “planned,” “potential,” “target,” “will” and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including the uncertainties inherent in pharmaceutical research and development; the rate of enrollment in studies of our product candidate(s); safety and efficacy of our product(s) and product candidate(s); the quality and manner of the data that will result from studies of our product candidate(s); risks associated with market acceptance and coverage and reimbursement of our product(s); risks associated with potential generic entrants for our product(s); the risk that clinical trials may not be successful; the risk that existing preclinical and clinical data may not be predictive of the results of ongoing or later clinical trials; manufacturing risks; risks associated with management and key personnel; the actual funding required to develop and commercialize our product candidate(s)and operate the company, and the actual expenses associated therewith; the actual costs incurred in the clinical studies of our product candidate(s)and the availability of financing to cover such costs; the risk that clinical studies are discontinued or delayed for any reason, including for safety, tolerability, enrollment, manufacturing or economic reasons; early termination of any of our collaborations; our and our collaborators’ ability to satisfy their obligations under our collaboration agreements; the timing and content of decisions made by regulatory authorities; the timing of any additional studies initiated for our product candidate(s); the actual time it takes to initiate and complete preclinical and clinical studies; the competitive landscape for our product(s) and product candidate(s); the scope, timing, and outcome of any ongoing legal, regulatory and administrative proceedings; changes in the economic and financial conditions of our and our collaborators’ businesses; the risk that we lose, or settle on unfavorable terms, litigation, as well as any other potential settlements; challenges to and our ability to obtain, maintain and enforce patent and other intellectual property protection for our product(s) and product candidate(s); trends toward managed care and health care cost containment; governmental laws and regulations affecting health care, including without limitation regarding pharmaceutical product access, pricing and reimbursement; and general economic conditions, such as interest rate and foreign currency exchange rate fluctuations. Other risks and uncertainties include those identified under the heading “Risk Factors” in our most recent Securities Exchange Commission filings, and other filings that we may make with the U.S. Securities and Exchange Commission in the future. These forward-looking statements (except as otherwise noted) speak only as of the date they are posted to this website (unless an earlier date is indicated), and we do not undertake, and specifically disclaim, any obligation to update any forward-looking statements contained in this website.

Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142

Driving Directions

+1 617.871.2098  phone
+1 617.871.2099  fax

Contact Us